title: [Bevacizumab in thoracic oncology: results and practical aspects].
abstract: Bevacizumab (Avastin(®)) is the first antiangiogenic therapy approved in non-small cell lung cancer (NSCLC). It is also currently the only agent in this family approved in NSCLC. This review focuses on results of clinical trials assessing bevacizumab in thoracic oncology. It also provides to clinicians practical advices for its prescription.
authors.affiliation: Département de cancérologie générale, CLCC Oscar-Lambret, 3, rue Fréderic-Combemale, BP 307, 59020 Lille cedex, France. e-dansin@o-lambret.fr
authors.forename: É
authors.initials: É
authors.lastname: Dansin
authors.forename: S
authors.initials: S
authors.lastname: Cousin
authors.forename: G
authors.initials: G
authors.lastname: Lauridant
authors.forename: B
authors.initials: B
authors.lastname: Mennecier
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008495:Medical Oncology; D011364:Professional Practice; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab